|
|
楼主 |
发表于 2013-4-17 03:31:51
|
显示全部楼层
来自： 美国
本帖最后由 kangaizhixin 于 2013-4-22 12:48 编辑
现将目前正在进行临床试验用化疗或放疗结合使用下面药物来治疗小细胞肺癌的靶向和其他药物例举一些供参考：
BAY1000394 (CDKi)
http://my.clevelandclinic.org/ca ... al.aspx?TrialID=564
View Cancer Clinical Trials
BAY 1512 | 12-1139
Phase Ib / II study of BAY 1000394 in combination with cisplatin / etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive disease small cell lung cancer
--------------------------------------------------------------------------------
Disease(s)
Lung
Hospital(s)
Main Campus
Phase(s)
Phase 1
Phase 2
Stage(s)
Type(s)
Therapeutic
Drug(s)
BAY 1000394
Carboplatin
Cisplatin
Etoposide
--------------------------------------------------------------------------------
Contact Information
Cancer Answer Line
866.223.8100
8:00 am - 4:30 pm, Monday - Friday
--------------------------------------------------------------------------------
Description
1.Phase Ib part of the study i.Primary: Determine the safety, tolerability, pharmacokinetics, and maximum tolerated dose of BAY 1000394 in combination with cisplatin / etoposide or carboplatin / etoposide chemotherapy in 2 separate cohorts in parallel
ii.Secondary: Assess the biomarker response profile of BAY 1000394, overall survival, progression-free survival, response rate, duration of response, stable disease and disease control rate
2.Phase II part of the study i.Primary: Evaluate the response rate in subjects with extensive disease SCLC receiving first-line cisplatin / etoposide or carboplatin / etoposide chemotherapy in combination with BAY 1000394. Tumor response will be evaluated based on RECIST 1.1. Tumor measurements will be made at baseline and then every 2 cycles, ie every 6 weeks based on 21-day cycles, until progressive disease will occur
ii.Secondary: Determine the tolerability, safety profile, biomarker response profile, overall survival, progression-free survival, duration of response, and stable disease and disease control rate for the combination of BAY 1000394 and chemotherapy and subsequent maintenance with BAY 1000394
LY2940680 (Hh gene inhibitor)
LY2510924 (CXCR4 inhibitor)
Avastin (anti-angiogenesis)
A service of the U.S. National Institutes of Health
Example: "Heart attack" AND "Los Angeles"
Search for studies:
Advanced Search
Help
Studies by Topic
Glossary
Find Studies »
About Clinical Studies »
Submit Studies »
Resources »
About This Site »
Text Size
Home
Find Studies
Study Record Detail
Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer
This study has been completed.
Sponsor:
GlaxoSmithKline
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00698516
First received: June 16, 2008
Last updated: March 22, 2012
Last verified: March 2011
History of Changes
Full Text View
Tabular View
Study Results
Disclaimer
How to Read a Study Record
Purpose
Combination of Hycamtin (topotecan) and Avastin (bevacizumab) could allow killing of both endothelial and neoplastic cells. We postulate that addition of bevacizumab to topotecan will increase delivery of topotecan to tumor cells and may enhance activity of topotecan in patients with previously treated small cell lung cancer and improve progression free survival.
Condition
Intervention
Phase
Recurrent Small-cell Lung Cancer (SCLC)
Lung Cancer, Small Cell
Drug: Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
Phase 2
Study Type:
Interventional
Study Design:
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title:
An Open-label, Multicenter, Non-comparative, Phase II Study of Oral Topotecan in Combination With Bevacizumab for Second-line Treatment in Subjects With Relapsed Small-cell Lung Cancer (SCLC)
Resource links provided by NLM:
MedlinePlus related topics: CancerLung Cancer
Drug Information available for: Topotecan hydrochlorideTopotecanBevacizumab
U.S. FDA Resources
Further study details as provided by GlaxoSmithKline:
Primary Outcome Measures: • ercentage of Participants With Progression-free Survival (PFS) at 3 Months [ Time Frame: 3 months ] [ Designated as safety issue: No ]
PFS = time from initiation of drug to time of first disease progression/death due to any cause. Progression assessed using Response Evaluation Criteria (RECIST): >=20% increase in sum of longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since treatment started, or appearance of new lesion(s). If participant did not progress or die, the time of initiation of post-treatment anti-cancer therapy or time of last contact used. PFS at 3 months calculated by taking the Kaplan-Meier (KM) estimate at 90 days from the initiation of treatment. SE = standard error.
OSI906 (IGF-1R inhibitor)
另外还有：
Pazopanib
Cabozantinib
Sorafenib
Arsenic Trioxide (砒霜） |
|
IP卡
狗仔卡
显身卡
发表于 2013-4-16 23:54:14
